Caroline Seymour


Age Associated With Survival, Time to Richter Transformation in AYA Patients With CLL

May 30, 2021

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

Immunotherapy in Ovarian Cancer: Don't Give Up, Yet

March 16, 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

New Treatment Methods Launch a Shift in CRC Treatment

March 13, 2021

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.

PARP Inhibitors Are a Mainstay in Metastatic Breast Cancer

March 08, 2021

Olaparib and talazoparib didn't show statistically significant improvements in overall survival compared with chemotherapy in certain patients with metastatic breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control.

CAR T-Cell Therapy Is Active, Safe in ALL

February 28, 2021

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.